Compare Cytokinetics Inc (CYTK) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Paycom Software Inc — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Paycom Software Inc trades at $230.01 (market cap $10.08B). The key difference: Paycom Software Inc is the larger of the two by market cap, and Paycom Software Inc pays a 0.67% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Paycom Software Inc for 84 Days on average.
| CYTK | PAYC | |
|---|---|---|
Market Cap | $8.50B | $10.08B |
Volume | 2,395,556 | 481,328 |
Sector | Health | Technology |
52-Week High | $87.26 | $240.52 |
52-Week Low | $54.76 | $113.59 |
Typical Hold Time | 19 Days | 84 Days |
Enterprise Value | $8.60B | $10.86B |
Dividend Yield | — | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
PAYC stock trades at $223.58, up 0.51% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 results, beating EPS estimates with 10% revenue growth and raised full-year guidance. Profitability remains robust with a net income margin of 22.78% and ROE of 41.09%. Recent news highlights institutional buying and positive momentum.
Outlook is positive given earnings momentum and raised guidance, but the stock trades above the consensus price target of $207.75, suggesting limited near-term upside. Risks include competitive pressures and reliance on labor market health. Analyst sentiment is mixed with 47% buy ratings versus 50% hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
